Animal Testing Ban in Mexico
Mexico has become the first country in North America to ban animal testing in cosmetic products. There are now 41 nations in the world that do not allow cosmetics to be tested on animals.
Picture of Marta Pinto

Marta Pinto

Regulatory Affairs Associate

MEXICO IS THE FIRST COUNTRY IN NORTH AMERICA TO BAN ANIMAL TESTING

In Mexico, it is no longer permitted to perform tests of cosmetic products on animals. The new law also bans the manufacture, import and marketing of cosmetic products tested on animal elsewhere in the world.

The Human Society International (HSI) and the organization ONG Te Protejo have campaigned side by side for years in order to achieve a proposed ban from the government. The stop-motion animated film ‘Save Ralph’ (from the HSI) has highly contributed for the decision of the Mexican government, as the video helped to generate more than 1.3 million petition signatures in Mexico. The film tells a story of a rabbit “tester” through voices from a multinational, multilingual cast of stars, and all the types of procedures that are carried out during testing of cosmetic products. The video went viral all over the world, having more than 150 million social media views and over 740 million tags on TikTok.

There are several cosmetic companies (Unilever, P&G, L’Oréal, Avon, Lush and others) that are working together with HSI through the Animal-Free Safety Assessment (AFSA) with the goal of creating curriculum to support smaller companies and government authorities to understand and trust the results of non-animal approaches in order to fully implement the animal testing bans.

The Executive Director for HSI, Antón Aguilar, said: “We thank the Mexican Government for showing leadership on this important issue, and we will continue to work with them to implement the commitments and enforce a robust ban. This is a monumental step forward for animals, consumers and science in Mexico, and this ground-breaking legislation leads the way for the Americas to become the next cruelty-free beauty market and brings us one bunny-leap closer to a global ban.”

There are now 41 countries (including Mexico) in the world that have prohibited animal testing for cosmetics. Moreover, 7 states in the US and 10 states in Brazil have also enacted bans. New Jersey, Rhode Island and New York are 3 U.S. states that are also currently considering similar bills and federal bills are pending reintroduction in the U.S. and Canada.

If you want to know more about non-animal approaches to cosmetic products testing and other related subjects, feel free to contact us at info@criticalcatalyst.com.

References:

  1. Human Society International (HSI). Be Cruelty-Free Campaign. Available from: [https://www.hsi.org/issues/be-cruelty-free/]
  2. Human Society International (HIS). News & Media. Mexico becomes first country in North America to outlaw animal testing for cosmetics. Semptember 2, 2021. Available from: [https://www.hsi.org/news-media/mexico-becomes-first-country-in-north-america-to-outlaw-animal-testing-for-cosmetics/]

further
reading

medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »